NASDAQ
2.34USD
-0.06 (-2.50%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
301.1M
P/E
—
EPS
—
Beta
1.33
52W range
2.04-7.077
Day range
2.33–2.46
Open
2.37
Prev close
2.40
Volume
753.3K
Avg volume
1.5M
Dividend
0.00
IPO
2017-01-05
https://seekingalpha.com/article/4914942-organogenesis-stock-mesmerized-by-wound-care-struggles-upcoming-renu-blockbuster-overlooked · 6/15/2026-1.00
https://www.globenewswire.com/news-release/2025/12/15/3205866/0/en/Organogenesis-Announces-Successful-FDA-Meeting-and-Plan-to-File-BLA-for-ReNu-for-Knee-Osteoarthritis-Pain.html · 12/15/2025+1.00
https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-organogenesis-holdings-inc---orgo-302582245.html · 10/13/2025-1.00
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works